Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Glaxo Wellcome

This article was originally published in The Tan Sheet

Executive Summary

Glaxo Wellcome: Low-dose Zantac (ranitidine hydrochloride) in 75 mg tablets is recommended for OTC regulatory approval in Austria, Belgium, France, Germany, Italy and Luxembourg under the EU's new centralized mutual recognition procedure. The Netherlands, which approved the product in December 1995, served as the reference member state. Zantac 75 was launched in the U.K. in January 1995 and the U.S. in April 1996. Warner-Lambert will handle marketing of the product in most countries under the two companies' joint venture agreement ("The Tan Sheet" July 8, In Brief)...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086192

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel